Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells

Curr Opin Investig Drugs. 2008 Nov;9(11):1216-27.

Abstract

Atacicept (TACI:Fc5) is a homodimeric fusion protein obtained through recombinant DNA technology being developed by Merck Serono SA, under license from ZymoGenetics Inc, for the potential treatment of B-cell diseases. Atacicept is undergoing phase II/III clinical trials for systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, as well as for several B-cell malignancies.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy
  • Clinical Trials as Topic
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Lupus Erythematosus, Systemic / drug therapy
  • Lymphoma, B-Cell / drug therapy
  • Multiple Myeloma / drug therapy
  • Recombinant Fusion Proteins / therapeutic use*
  • Structure-Activity Relationship

Substances

  • Recombinant Fusion Proteins
  • TACI receptor-IgG Fc fragment fusion protein